Skip to main content

OrbiMed — Portfolio, Page 10

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

289
Companies
$23.6B
Total invested
$104.0M
Avg. check
19
Industries
Biotechnology 20Health Care 16Therapeutics 8Medical 8Pharmaceutical 5Wellness 4+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 217240 of 289
Aeglea BioTherapeutics
June 2023

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Biotechnology · Austin$210.0M Post Ipo Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
Stemirna
May 2023

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science.

Biotechnology · BeijingSeries D
Ikena Oncology
May 2023

Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.

Biotechnology · Boston$40.0M Post Ipo Equity
Amolyt Pharma
January 2023

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Biotechnology · Écully$138.6M Series C
Ruipeng Pet Healthcare
December 2022

Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator.

Beauty · ShenzhenPrivate Equity
iECURE
November 2022

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Biotechnology · Philadelphia$65.0M Series A
Immvira
October 2022

Immvira’s scientific objectives are based on numerous experimental designs of oHSV and outcomes of clinical trials.

Clinical Trials · ShenzhenSeries C
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
Dami&Xiaomi
July 2022

Dami&Xiaomi is a child autism intervention agency.

Health Care · Shenzhen$42.0M Series D
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
Frontera Therapeutics
June 2022

Frontera Therapeutics is an AAV gene therapy company that focuses on rAAV therapies for the global market.

Biotechnology · Bedford$160.0M Series B
Chinook Therapeutics
May 2022

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.

Biotechnology · Vancouver$105.0M Post Ipo Equity
Laekna Therapeutics
May 2022

Laekna Therapeutics is a biotech company focusing on drug discovery and development.

Biotechnology · Shanghai$61.0M Series D
Puma Biotechnology
March 2022

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

Biotechnology · Los Angeles$10.0M Post Ipo Equity
MDClone
March 2022

MDClone offers a powerful, self-service data analytics environment enabling healthcare collaboration, research, and innovation.

Analytics · Be'er Sheva$63.0M Series C
HanBio Therapeutics
January 2022

HanBio Therapeutics is a biotechnology company committed to researching and developing next generation transformative medicines.

Biotechnology · Shanghai$40.0M Series A
Gennao Bio
December 2021

Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.

Biotechnology · New York$1.0M Series A
Emergence Therapeutics
December 2021

Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.

Biotechnology · Duisburg$98.1M Series A
Edge Medical Robotics
November 2021

Edge Medical Robotics is a surgical robot platform company focused on design, R&D, and commercialization of advance medical devices.

Health Care · Shenzhen$200.0M Series C
PierianDx
November 2021

PierianDx is catalyzing global adoption of genomic sequencing in healthcare

Biotechnology · St Louis$30.0M Series Unknown
Repare Therapeutics
October 2021

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

Biotechnology · Saint Laurent$101.2M Post Ipo Equity
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B

Where OrbiMed invests

Biotechnology20
Health Care16
Therapeutics8
Medical8
Pharmaceutical5
Wellness4

About OrbiMed's portfolio

How many companies has OrbiMed invested in?

OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does OrbiMed invest in?

OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 19 different industry categories.

What is OrbiMed's largest investment?

Among tracked funding rounds, ACELYRIN received $300.0M in a Series C round. OrbiMed's total known invested capital is $23.6B.

What is the average investment size for OrbiMed?

OrbiMed's average investment size is $104.0M across its portfolio of 289 companies.

What are OrbiMed's most recent investments?

Recent OrbiMed portfolio additions include Aeglea BioTherapeutics, Upstream Bio, Stemirna, Ikena Oncology, Amolyt Pharma. These companies were founded in 2020 or later.

Reach the founders behind these 289 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →